Company intelligence / Profile preview

Tessellation

Amsterdam, Netherlandstessellationgames.com ↗

Ownership: Private
Development stage: Other

Overview

Tessellate Bio is a preclinical-stage biotechnology company developing first-in-class, small molecule precision oncology medicines using novel synthetic lethality approaches. Its lead program targets cancers dependent on the ALT pathway via the FANCM protein complex, and another program addresses cancers with RB1 loss-of-function. The company is also developing companion diagnostics to identify eligible patients. No clinical results have been reported as all programs are preclinical as of June 2025

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Tessellation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tessellation.

Explore the full profile